Dyslipidemia International Survey-China (DYSIS-China)

Dyslipidemia International Survey - China

This cross-sectional, non-interventional, and observational study will assess the lipid profile of patients who have been taking lipid-modifying drugs (i.e., proportion of patients achieving treatment to goal according to national and international lipid management guidelines) during a single visit to their physicians on an outpatient basis in 6 representative geo-economic regions in China: Northeast, North, East, South, Southwest, and Northwest; and within each region, in three tiers of hospitals: tier 3 (primary or teaching hospitals), tier 2 (secondary or city level hospitals), and tier 1 (community hospitals/health centers). The investigators will primarily be cardiologists, endocrinologists, neurologists, gerontologists, internists, or other physicians who are representative of the general population of physicians managing patients with dyslipidemia and/or at high risk for cardiovascular events likely to be treated with lipid-modifying drugs. Demographic data, cardiovascular risk factors, a history of cardiovascular disease and cardiovascular treatments will be documented in a single visit through patient clinical examination and chart review.

DYSIS-China is part of a string of epidemiological studies that share the same master protocol, which has been conducted in different countries mainly in Europe and Canada. The analysis of the pooled studies including overall data and cross-country comparisons is the subject of a distinct protocol.

Study Overview

• Status: Unknown
• Conditions: the Prevalence,Lipid Abnormalities,

• Study Type: Observational
• Enrollment (Anticipated): 25000

Contacts and Locations

Study Locations

• China
  • Beijing
    • Beijing, Beijing, China, 100044
      • Recruiting
      • Peiking University People' Hospital
      • Contact: Ding Rong Jing, Dr.; Phone Number: 0108688325940; Email: drj2003@sina.com
      • Sub-Investigator: Ding rong jing, Dr.

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 45 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Probability Sample

Study Population

1. Patient is an outpatient > 45 years of age
2. Patient is currently* treated with a statin
3. Patient has a documented fasting lipid profile (> 1 lipid parameter within the last 12 months) performed while on lipid-modifying therapy for at least 3 months

4. Patient agrees to participate in the study by giving informed consent.

   • Patient is already being treated with a lipid-modifying drug just before the visit. Patient for whom a lipid-modifying therapy is initiated at the time of the visit must not be included.

Description

Inclusion Criteria:

1. Patient is an outpatient > 45 years of age
2. Patient is currently* treated with a statin
3. Patient has a documented fasting lipid profile (> 1 lipid parameter within the last 12 months) performed while on lipid-modifying therapy for at least 3 months

4. Patient agrees to participate in the study by giving informed consent.

   • Patient is already being treated with a lipid-modifying drug just before the visit. Patient for whom a lipid-modifying therapy is initiated at the time of the visit must not be included.

Exclusion Criteria:

1. Patient is currently participating in a clinical trial.

Study Plan

How is the study designed?

Design Details

• Observational Models: Case-Only
• Time Perspectives: Cross-Sectional

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort
regions,hospitals,age, gender, risk levels, comorbidity,

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
the prevalence and types of persistent lipid abnormalities in patients aged > 45 years treated with a lipid-modifying drug	6 months

Secondary Outcome Measures

Outcome Measure	Time Frame
assess patient characteristics, including CV risk levels, in the subsets of patients with persistent lipid abnormalities	6months

Other Outcome Measures

Outcome Measure	Time Frame
explore a potential relationship between the persistence of lipid abnormalities and the local known (historical) prevalence of CV morbidity/mortality	6months

Collaborators and Investigators

• Sponsor: Chinese Society of Cardiology
• Investigators: Principal Investigator: Hu da yi, Dr., Chinese Society of Cardiology

Publications and helpful links

General Publications

• Chen Y, Yin C, Li Q, Yu L, Zhu L, Hu D, Sun Y. Misuse of Aspirin and Associated Factors for the Primary Prevention of Cardiovascular Disease. Front Cardiovasc Med. 2021 Sep 3;8:720113. doi: 10.3389/fcvm.2021.720113. eCollection 2021.
• Yan X, Li Y, Dong Y, Wu Y, Li J, Bian R, Hu D. Blood pressure and low-density lipoprotein cholesterol control status in Chinese hypertensive dyslipidemia patients during lipid-lowering therapy. Lipids Health Dis. 2019 Jan 29;18(1):32. doi: 10.1186/s12944-019-0974-y.

Study record dates

Study Major Dates

• Study Start: February 1, 2012
• Primary Completion (Actual): April 1, 2012
• Study Completion (Anticipated): December 1, 2012

Study Registration Dates

• First Submitted: November 20, 2012
• First Submitted That Met QC Criteria: November 23, 2012
• First Posted (Estimate): November 26, 2012

Study Record Updates

• Last Update Posted (Estimate): November 26, 2012
• Last Update Submitted That Met QC Criteria: November 23, 2012
• Last Verified: November 1, 2012

More Information

Terms related to this study

• Keywords: the prevalence,lipid abnormalities,CV risks
• Additional Relevant MeSH Terms: Metabolic Diseases; Lipid Metabolism Disorders; Dyslipidemias; Congenital Abnormalities
• Other Study ID Numbers: 0000-271-0